about
Epigenome-modifying tools in asthmamicroRNA expression in the aging mouse lung.Expression profiling in vivo demonstrates rapid changes in lung microRNA levels following lipopolysaccharide-induced inflammation but not in the anti-inflammatory action of glucocorticoids.MicroRNA expression profiling in mild asthmatic human airways and effect of corticosteroid therapy.Role of non-coding RNAs in maintaining primary airway smooth muscle cellsPharmacological studies of the mechanism and function of interleukin-1beta-induced miRNA-146a expression in primary human airway smooth muscle.Maternally imprinted microRNAs are differentially expressed during mouse and human lung developmentRapid changes in microRNA-146a expression negatively regulate the IL-1beta-induced inflammatory response in human lung alveolar epithelial cells.BET bromodomains regulate transforming growth factor-β-induced proliferation and cytokine release in asthmatic airway smooth muscle.Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity.Airway smooth muscle hyperproliferation is regulated by microRNA-221 in severe asthma.Transcriptional profiling identifies the long noncoding RNA plasmacytoma variant translocation (PVT1) as a novel regulator of the asthmatic phenotype in human airway smooth muscle.Mechanisms of glucocorticoid action and insensitivity in airways disease.Role of microRNAs in allergic asthma: present and future.Airway smooth muscle inflammation is regulated by microRNA-145 in COPD.Noncoding RNAs and Duchenne muscular dystrophy.The anti-proliferative and anti-inflammatory response of COPD airway smooth muscle cells to hydrogen sulfide.Divergent intracellular pathways regulate interleukin-1beta-induced miR-146a and miR-146b expression and chemokine release in human alveolar epithelial cells
P50
Q28083520-1E959A3F-9008-4360-A8D2-E38D4375A1A1Q33287967-8050C1BF-4E7E-42FD-ABAA-97151D69F203Q33291235-549BD283-00A1-4FAD-8FBC-3AAF8E92C825Q33466773-F1B68DD8-9888-4AE4-925B-73268D87A14EQ33690703-59B896B8-AA66-4233-88E2-20251FE8F829Q33951715-1A43A519-CF00-4776-80EA-272321575D62Q34595147-1D33A506-2E3C-4568-9B91-0257453E2A3BQ34768042-CB1DE17F-1E7B-476A-8699-01D7375CD8F5Q35580851-C30725E7-373E-4746-8965-4666070BA2AAQ37052581-1A3F2BC7-4F28-47CB-A4DD-72B13C0D7671Q37596092-07CA3989-77D3-4103-BE75-8C228569A261Q37682717-C9CAB6F1-4FAD-4A1F-B153-AB690E2C7CE3Q38248898-142A8900-03BB-49F5-BF44-D9A543F35276Q38471714-717E07B9-3F86-44FD-B3EC-02607C594F58Q42379467-BD2836F5-E1C3-4C90-9706-56F361C83B5FQ50479884-33F65766-F468-42AA-BF53-A43C42067C11Q55098060-F0A857E8-B153-483C-82F7-CCA13F311534Q84592072-CFE25F04-7310-40CB-97CD-0EA1087646F6
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mark M Perry
@nl
Mark M Perry
@sl
Mark M. Perry
@en
Mark M. Perry
@es
type
label
Mark M Perry
@nl
Mark M Perry
@sl
Mark M. Perry
@en
Mark M. Perry
@es
prefLabel
Mark M Perry
@nl
Mark M Perry
@sl
Mark M. Perry
@en
Mark M. Perry
@es
P106
P1153
36885616500
P31
P496
0000-0002-8145-8042